Show filtering options
ABSTRACT TYPES
Oral Abstract
Poster Discussion
Poster Exhibition
Publication Only
PRESENTATION DAYS
Sunday, 19 July
Monday, 20 July
Tuesday, 21 July
Wednesday, 22 July
 
  • Track A : Basic Science
    • Adaptive Immune Responses
    • Animal Models (Excluding Latency/Reservoirs)
    • Basic Retrovirology
    • Diagnostic Tools for Immunological and Virological Monitoring of HIV Infection
    • HIV Evolution and phylodynamics (intra- and inter-host)
    • HIV Pathogenesis / Immune Function and Dysfunction
    • HIV/SIV Latency and Viral Reservoirs (Human and Animal Models)
    • Host Genetics and Systems Biology
    • Innate Immune Responses
    • Natural Protection Against HIV/AIDS
    • Novel Treatment, Prevention and Cure Strategies
    • Super- and Co-Infections (Including Opportunistic Infections)
    • Transmission and Early Infection
    • Vaccine Development
  • Track B : Clinical Science
    • Antiretroviral Therapies in Adults (Clinical Trials and Observational Cohort Studies)
    • Co-Infections (Including Opportunistic Infections)
    • Co-Morbidities and Complications (Including those related to ART)
    • Course of HIV Disease
    • Diagnostic and Monitoring Tools
    • Linkage and Retention in Care
    • Other Strategies and Therapies (Non-ART)
    • Specific Issues Related to HIV Infection and Treatment in Children and Adolescents
    • Specific Issues Related to HIV Infection and Treatment in Key Populations
    • Specific Issues Related to HIV Infection and Treatment in Women
  • Track C : Prevention Science
    • Approaches and Tools for HIV Prevention
    • Epidemiology of HIV
    • Feasibility and Impact of Structural Interventions
    • HIV Surveillance
    • Methodological Issues and Capacity-Building
    • Population-Specific Interventions and HIV Prevention Strategies
    • Prevention of Mother-to-Child Transmission
  • Track D : Implementation Science
    • Diagnostics
    • Health Systems Strengthening
    • Infrastructure and Delivery Models for the Scale Up of HIV Services
    • Integration of HIV Services with Other Programmes
    • Interventions to Increase Uptake and Retention in HIV Services
    • Monitoring and Evaluation
    • Sustainable Financing
A66A murine viral outgrowth assay to detect HIV in patients with undetectable viral loadsMOAA0101 Oral Abstract
A36Virologic and immunologic correlates of viral control post-ART interruption in SIV-infected rhesus macaquesMOAA0102 Oral Abstract
A35Anti-HIV antibody responses reflect the quantifiable HIV reservoir sizeMOAA0103 Oral Abstract
A33Trancriptomics and metabolomics identify inflammatory profiles that segregate subjects with high and low inducible HIV reservoirMOAA0104 Oral Abstract
A36HIV-1 virological remission for more than 11 years after interruption of early initiated antiretroviral therapy in a perinatally-infected childMOAA0105LB Oral Abstract
A35Time associated changes in cell-associated HIV RNA in HIV-infected subjects on suppressive antiretroviral therapy - implications for clinical trials of cure interventionsMOAA0106LB Oral Abstract
A52Treatment with anti-α4β7 integrin antibody reduces virus-mediated gastrointestinal pathology by targeting distinct mucosal tissuesMOAA0202 Oral Abstract
A30Oral microbiome in HIV-infected women: aging, disease progression and opportunistic infections increase the pathogenic profileMOAA0203 Oral Abstract
A24Serum-derived bovine immunoglobulin isolate increases peripheral and mucosal CD4 T cell count in patients with HIV enteropathyMOAA0204 Oral Abstract
A54HIV-exposure, gut microbiome, and vaccine responses in South African infantsMOAA0205 Oral Abstract
A13SIV-induced translocation of bacterial products in the liver mobilizes myeloid dendritic and natural killer cells associated with liver damageMOAA0206LB Oral Abstract
A67Low frequency HIV drug resistance in Ugandan patients failing ART with susceptible HIV Sanger genotypingMOLBPE01 Poster Exhibition
A2Within-host evolution of X4 HIV-1 in a rare transmission pair revealed by phylogenetic reconstruction of deep-sequence dataMOPDA0101 Poster Discussion Abstract
A40Genetic ancestry component proportions are correlated with HIV disease progressionMOPDA0102 Poster Discussion Abstract
A33Dasatinib preserves SAMHD1 antiviral activity in CD4+ T cells treated with IL-7MOPDA0103 Poster Discussion Abstract
A51HIV-specific latency reversing therapies that exploit novel pathways for suboptimal Tat protein expressionMOPDA0104 Poster Discussion Abstract
A51HIV rebound and meningoencephalitis following ART interruption after allogeneic hematopoietic stem cell transplant: an investigation of the source of HIV reboundMOPDA0105 Poster Discussion Abstract
A35Assay to measure the latent reservoir of replication-competent HIV-1 in suppressed patients based on ultra deep sequencingMOPDA0106LB Poster Discussion Abstract
A17Monoclonal antibodies using IgG-V regions from cows vaccinated with HIV gp140 require cysteine and tryptophan for high affinity Env trimer-specific bindingMOPEA001 Poster Exhibition
A18Early initiation of treatment in primary HIV infection leads to temporary preservation of the B-cell compartmentMOPEA002 Poster Exhibition
A18Numerical and phenotypic B-cell abnormalities and vaccine responses in HIV-exposed uninfected (HEU) childrenMOPEA003 Poster Exhibition
A19Control of HIV-1 by cytotoxic T cells specific for multiple conserved epitopesMOPEA004 Poster Exhibition
A20Bacterial vaginosis is associated with loss of gamma delta T cells in the female reproductive tractMOPEA005 Poster Exhibition
A20Effects of quadruple first-line ART on mucosal immunity and HIV persistenceMOPEA006 Poster Exhibition
A20Hormonal contraception and cervical immunity before and after HIV acquisitionMOPEA007 Poster Exhibition
A21 Reporter assay to measure HIV-1 Nef-mediated evasion from T cellsMOPEA008 Poster Exhibition
A21 Nef and Vpu accessory proteins from primary HIV-1 isolates protect infected cells from ADCCMOPEA009 Poster Exhibition
A21 Novel approach to identify new ADCC-mediating antibodies targeting the HIV-1 envelopeMOPEA010 Poster Exhibition
A21 Identification of HLA-associated polymorphisms in a cohort of HIV-1 subtype A/E infectionMOPEA011 Poster Exhibition
A36Profound alterations in cholesterol metabolism restrict HIV-1 trans infection of CD4 T cells in nonprogressorsMOPEA013 Poster Exhibition
A37Characterization of anti-gp41 antibodies eliciting viral neutralization and protecting against CD4 depletion in long-term non-progressorsMOPEA014 Poster Exhibition
A37CD40L-induced tunneling nanotube networks facilitate proinflammatory dendritic cell-mediated HIV-1 trans-infection of CD4+ T cellsMOPEA015 Poster Exhibition
A38Plasma and PBMC miRNA profile in sexually HIV-exposed seronegative individualsMOPEA016 Poster Exhibition
A38Immune activation is present in HIV-1 exposed seronegative individuals (HESN) and is indipendent from microbial translocationMOPEA017 Poster Exhibition
A39Association of the presence of HIV-1 broadly neutralizing antibodies during pregnancy and prevention of mother to child transmission at deliveryMOPEA018 Poster Exhibition
A39Neutralizing antibody response in chronically HIV-1 infected ART naïve children from India: a follow-up studyMOPEA019 Poster Exhibition
A39Identification of the structural determinants for the selective anti-HIV-1 activity of the all-β alternative conformer of the γ-chemokine XCL1/lymphotactinMOPEA020 Poster Exhibition
A42Effect of rectal gonorrhea and chlamydia on cytokine expression and HIV viral load in the rectumMOPEA021 Poster Exhibition
A42CD161-expression on CD4+ T cells is enriched in the female genital tract and identifies a subset of activated cells rather than Th17 commitment as in bloodMOPEA022 Poster Exhibition
A42HIV-1 Nef controls cellular invasion through differential modulation of host proteinsMOPEA023 Poster Exhibition
A45Galectin-3 promotes HIV-1 cell-to-cell transmission via up-regulating GM1 ganglioside in lipid raft of CD4+ T cellsMOPEA024 Poster Exhibition
A46Early antiretroviral treatment (ART) fails to achieve sustained HIV viral remission but limits viral diversityMOPEA025 Poster Exhibition
A54Strong functional constraint at residues in HIV-1 Gag are predicted by measures of evolutionary rather than population-level genetic conservationMOPEA026 Poster Exhibition
A54Effect of losartan on lymphoid tissue fibrosis and inflammation in virologically suppressed HIV patients after 48 weeksMOPEA027 Poster Exhibition
A55Modulation of binding antibody responses to trimeric gp145 and gp41 HIV-1 envelope proteins by utilizing different adjuvants and delivery platforms as a prime-boost strategyMOPEA028 Poster Exhibition
A56pVLP: a new DNA vaccine strategy for HIVMOPEA029 Poster Exhibition
A56Deletion of immunomodulatory A44L, A46R and C12L viral genes from Modified Vaccinia Ankara (MVA) genome: effect on its immunogenicityMOPEA030 Poster Exhibition
A56Generating an anti-HIV vaccine using lipid nanoparticle-encapsulated nucleoside-modified mRNA encoding envelopeMOPEA031 Poster Exhibition
A56Immunological characterization of an HIV vaccine comprised of Gag and dgp41 virus-like particles produced both in plants and by live Vaccinia virus vectorsMOPEA032 Poster Exhibition
A57Monocyte-derived DC electroporated with mRNAs encoding both specific HIV antigens and DC adjuvants are able to improve T cell functionalityMOPEA033 Poster Exhibition
A57Therapeutic conserved elements (CE) DNA vaccine increases T cell responses against highly conserved viral sequences in the setting of pre-existing immunodominant responses induced by chronic viral infectionMOPEA034 Poster Exhibition
A57Immune response to sequences surrounding the 12 protease cleavage sites generated during ARV treatment improved CD4 counts of SIVmac251 infected rhesus monkeysMOPEA035 Poster Exhibition
A57Safety and immunogenicity of ChAd.HIVconsv and MVA.HIVconsv therapeutic vaccines in a cohort of early treated HIV-1 infected individualsMOPEA036 Poster Exhibition
A57Development of a latency reversing activator vaccine (ACT-VEC) platform for HIV-1 cure therapyMOPEA037 Poster Exhibition
A57VAC-3S immunotherapeutic HIV vaccine combined with ART is immunogenic and safe. Phase II initial analysis of the IPROTECT1 multicenter European studyMOPEA038 Poster Exhibition
A57Broadly specific, cytolytic T cell responses and lower inflammatory responses correlate with durable viral remission following therapuetic DNA vaccination in SIV-infected macaquesMOPEA039 Poster Exhibition
A58Prevalence and clinical impacts of HIV-1 intersubtype recombinants in UgandaMOPEA040 Poster Exhibition
A60Stability of the NS3 Q80K polymorphism over time within HCV genotype 1a infected patientsMOPEA041 Poster Exhibition
A60Discovery of a novel class of naturally occurring indirect-acting antiviral agents against both HIV-1 and hepatitis C virus infectionMOPEA042 Poster Exhibition
A65Changes in concentrations of circulating calprotectin and S100A9 in successfully treated HIV-1 patients over timeMOPEA043 Poster Exhibition
A65External quality assurance improves both domestic and international laboratory performance for peripheral blood mononuclear cell cryopreservationMOPEA044 Poster Exhibition
A67Applying TRIP technology to visualise latent HIV-1 integrations on chromosome landscapesMOPEA045 Poster Exhibition
A67Determination of integrase inhibitor resistance using a novel HIV phenotype assayMOPEA046 Poster Exhibition
A70SIVagm from vervet African green monkeys can utilize non-CCR5 entry pathways in vitro and ex vivoMOPEA047 Poster Exhibition
A71Probing and characterizing resistance to integrase inhibitors using simian immunodeficiency virus 239MOPEA048 Poster Exhibition
A18HIV-induced abnormalities of the B-cell compartment persist in patients on long-term ART and may reflect a state of terminal B-cell exhaustionPUB001 Publication Only
A35Flow-based differentiation between latently HIV-1-infected single cells expressing Gag mRNA alone or in conjunction with Gag protein following latency reversalPUB002 Publication Only
A35Improved assays to measure the inducible latent HIV reservoirPUB003 Publication Only
A42The tip of the iceberg: impact of asymptomatic STI's on immune cells in the male foreskinPUB004 Publication Only
A51Reversal of HIV-1 latency by activation of patient-derived CD4+T-cells results in clonal expansion and sustained production of infectious virus from a subset of cellsPUB005 Publication Only
A2Phylogenetically estimated HIV diversification rates reveal prevention of HIV-1 by antiretroviral therapyTUAA0101 Oral Abstract
A45Phenotypic properties influencing HIV-1 transmission fitnessTUAA0102 Oral Abstract
A1Population-level spread of immune-driven mutations in HIV-1 polymerase during the North American epidemicTUAA0103 Oral Abstract
A6Primary resistance against dolutegravir decreases HIV integrationTUAA0104 Oral Abstract
A6HIV-1 integrase variants retarget proviral integration and are associated with disease progressionTUAA0105 Oral Abstract
A40HIV-1 specific IgG antibody levels correlate with presence of a specific HLA class II allele to impact acquisition and vaccine efficacyTUAA0106LB Oral Abstract
A51Zinc finger nuclease gene editing for functional cure in a nonhuman primate model of HIV/AIDSTUAA0202 Oral Abstract
A71Crispr/Cas9 gene editing eradicates latent and protects cells against new HIV-1 infectionTUAA0203 Oral Abstract
A34Investigating the role of the immune checkpoint receptor TIGIT in T cells during HIV disease progression and as a target for immune restorationTUAA0204LB Oral Abstract
A33Estrogen blocks HIV re-emergence from latency and points to gender-specific differences in HIV reservoirsTUAA0205LB Oral Abstract
A51Novel activators of latent HIV-1 from natural productsTULBPE02 Poster Exhibition
A52CD4 mimetics sensitize HIV-1-infected cells to ADCCTULBPE03 Poster Exhibition
A52Enhancement of microbiota in healthy macaques results in robust beneficial modulation of mucosal and systemic immune functionTULBPE04 Poster Exhibition
A29Association between CSF and peripheral markers of immune-activation/inflammation and elevated intrathecal HIV-RNA levels in a cohort of HIV-infected antiretroviral naïve individualsTUPDA0101 Poster Discussion Abstract
A13Receptor mediated endocytosis directs subcellular trafficking and TLR signaling of HIV-1 in plasmacytoid dendritic cellsTUPDA0102 Poster Discussion Abstract
A11HIV-1 Vpu exploits the crosstalk between BST2 and the ILT7 receptor to inhibit innate sensing of infected T cells by plasmacytoid dendritic cellsTUPDA0103 Poster Discussion Abstract
A8HIV-1 transcriptional silencing caused by TRIM22 inhibition of Sp1 binding to the promoterTUPDA0104 Poster Discussion Abstract
A11Polymorphisms in TRIM22 are associated with HIV-2 acquisition and disease progressionTUPDA0105 Poster Discussion Abstract
A26The negative checkpoint receptor TIGIT marks exhausted T cells during SIV infection and correlates with SIV disease progressionTUPDA0106LB Poster Discussion Abstract
A1Phylogenetic estimation of the temporal spread of hepatitis C genotype 1a in North AmericaTUPEA049 Poster Exhibition
A1Origin and evolutionary history of HIV-2 in CubaTUPEA050 Poster Exhibition
A2Molecular epidemiology of clinical HIV-1 pol sequences isolated between January 2009 and July 2013 in CubaTUPEA051 Poster Exhibition
A2The Local Dissemination Impact of the HIV-1 env LDI tripeptide α4β7 binding motifTUPEA052 Poster Exhibition
A2Evolution of the HIV-1 envelope gene during suppressive cARTTUPEA053 Poster Exhibition
A2Multiplexed highly-accurate next-generation sequencing of mixtures of full-length HIV genome variantsTUPEA054 Poster Exhibition
A2HIV-1 circular recombinant CRF02-AG: rapid spread in Russia and neighboring countriesTUPEA055 Poster Exhibition
A2A new framework for reconstructing epidemic dynamics from virus sequences: model validation and application to the HIV CRF07-BC epidemic in ChinaTUPEA056 Poster Exhibition
A2Prevalence, evolutionary dynamics and transmission pattern of HCV, HIV-1 and HPgV among injecting drug usersTUPEA057 Poster Exhibition
A2Identification and genetic characterisation of a novel HIV-1 circulating recombinant lineage (CRF74_01B) among people who inject drugs in MalaysiaTUPEA058 Poster Exhibition
A2Kive: a framework for version control of bioinformatic pipelines and data, and its application to HIV resistance genotypingTUPEA059 Poster Exhibition
A2Newly diagnosed HIV-1 infections in Spain frequently group in clusters of subtype B and non-subtype B genetic formsTUPEA060 Poster Exhibition
A2Prevalence of defective HIV-1 genome in HIV-infected patients on long-term cART and correlation with characteristics of patientsTUPEA061 Poster Exhibition
A2Full-length ultra-deep sequencing of HIV-1 transmission partners reveals the impact of intra-host evolution on immune controlTUPEA062 Poster Exhibition
A3Consequences of HLA-B*13-associated escape mutations on HIV-1 replication and Nef protein functionTUPEA063 Poster Exhibition
A3Drug susceptibility and viral fitness of integrase strand transfer inhibitor and nucleoside reverse transcriptase inhibitor resistance mutations in combinationTUPEA064 Poster Exhibition
A3SIV CTL escape mutations resulting in loss of viral fitness can be maintained after transmission into MHC-I-mismatched hostsTUPEA065 Poster Exhibition
A4Transmission dynamics of local networks of transmitted resistance to NNRTIs suggest an increasing incidence over time in Greece: the added value of molecular epidemiology to public healthTUPEA066 Poster Exhibition
A4HIV resistance pathways support the use of lamivudine (3TC) and dolutegravir (DTG) in combinationTUPEA067 Poster Exhibition
A4Evolution of HIV-1 integrase following selection of R263K with further dolutegravir treatment: a case report from the P1093 studyTUPEA068 Poster Exhibition
A40Degradation of HIV-1 Nef by ubiquitin (Ub) specific protease 15 (USP15)TUPEA069 Poster Exhibition
A40Independent association of host immunogenetic factors with vertical HIV transmissionTUPEA070 Poster Exhibition
A40Expression analysis of α4 integrin and related genetic polymorphisms in HIV acquisition and disease progression of infected individualsTUPEA071 Poster Exhibition
A40Human leukocyte antigen (HLA) typing and novel allele description by next generation sequencing in HIV-1-infected individuals from Southern BrazilTUPEA072 Poster Exhibition
A40Absence of an association between mannose binding lectin deficiency and HIV-1 disease progression in an adult population in ZimbabweTUPEA073 Poster Exhibition
A41Global mapping of HIV-1 and host-cells molecular interactionsTUPEA074 Poster Exhibition
A47TLR7 agonist GS-9620 is a potent inhibitor of acute HIV-1 infection in human PBMCsTUPEA075 Poster Exhibition
A47A novel acylguanidine-based inhibitor of HIV-1 egressTUPEA076 Poster Exhibition
A47Novel CD4-mimetic small molecules show enhancement of the neutralization activity of anti-cryptic V3 neutralizing antibody, KD-247TUPEA077 Poster Exhibition
A47BMS-955176: characterization of a 2nd-generation HIV-1 maturation inhibitorTUPEA078 Poster Exhibition
A47Small molecule activator of protein phosphatase 1 (SMAPP1) activates latent HIV-1 provirusTUPEA079 Poster Exhibition
A47Discovery and anti-HIV-1 activity of a new class of diheteroarylamide-type anti-HIV-1 agents acting on HIV-1 alternative splicingTUPEA080 Poster Exhibition
A47Discovery of novel HIV-1 inhibitors from natural productsTUPEA081 Poster Exhibition
A47Development of efficient parallel synthesis strategies for the generation of compound libraries of anti-HIV agents that alter HIV alternative splicingTUPEA082 Poster Exhibition
A49Antiviral activity of 5-Hydroxytyrosol, a microbicidal candidate against HIV-1 transmissionTUPEA083 Poster Exhibition
A49Protection from HIV-1 infection by S-layer mediated display of anti-HIV proteins on Caulobacter crescentusTUPEA084 Poster Exhibition
A51MG1 and VSVΔ51 viruses target and kill latently HIV-infected myeloid cellsTUPEA085 Poster Exhibition
A51Risk of virologic rebound in HIV-infected patients on HAART with very low-level viraemiaTUPEA086 Poster Exhibition
A51Minimal HIV-1 Gag epitope presentation in a T cell line during reactivationTUPEA087 Poster Exhibition
A51Vorinostat, panobinostat and romidepsin nonselectively activate transcription from quiescent HIV-1 proviruses in HIV-infected individuals on long-term suppressive antiretroviral therapyTUPEA088 Poster Exhibition
A51Combinatorial CRISPR/Cas9 approaches targeting different steps in the HIV life cycle efficiently limits viral reactivation and halts viral replicationTUPEA089 Poster Exhibition
A51Universal Tre-recombinase (uTre) specifically targets the majority of primary HIV-1 isolatesTUPEA090 Poster Exhibition
A51Polyvalent immune responses correlate with lower number of HIV-infected CD4 T cells in chronically infected subjects treated with autologous RNA pulsed DC therapyTUPEA091 Poster Exhibition
A51Latency reversal Agent (LRA) romidepsin reactivates latent virus in two rhesus macaque (RM) models of controlled SIV infection in the absence of antiretroviral therapy (ART)TUPEA092 Poster Exhibition
A51Robust HIV-specific T cells in post-treatment controllers from the VISCONTI cohortTUPEA093 Poster Exhibition
A51Nef inhibition for enhanced NK cell killing of cells expressing reactivated HIV-1TUPEA094 Poster Exhibition
A51Emergence of infectious treatment-resistant HIV after provirus-directed endonuclease therapyTUPEA095 Poster Exhibition
A52Selection and evaluation of specific single chain antibodies against gp41 of HIVTUPEA096 Poster Exhibition
A52Antibody-dependent cellular cytotoxicity against cells latently infected with HIVTUPEA097 Poster Exhibition
A52Potent and broad neutralizing activity of small antibody fragments targeting CD4i (CD4-induced) epitopeTUPEA098 Poster Exhibition
A52A novel TLR-9 agonist (MGN1703) activates NK-cells and enhances NK-cell mediated viral killing of HIV-1 infected CD4+ T cells ex vivoTUPEA099 Poster Exhibition
A17Comparison of HIV-1 envelope specific IgA and IgG antiviral ability to prevent HIV-1 infection: additive, inhibitory and synergistic effectsWEAA0101 Oral Abstract
A17Anti-V3/glycan and anti-MPER neutralizing antibodies, but not anti-V2/glycan-site antibodies are strongly associated with higher anti-HIV-1 neutralization breadth and potencyWEAA0102 Oral Abstract
A40Impact of HLA-B*35 alleles on HIV disease outcome in Mexico and Central AmericaWEAA0103 Oral Abstract
A51Type-1 programmed dendritic cells induce primary CTL capable of effectively targeting the HIV-1 reservoirWEAA0104 Oral Abstract
A34Molecular determinants of HIV-1 permissiveness and persistence in gut-homing CD4+ T cells expressing the Th17 marker CCR6WEAA0105 Oral Abstract
A56The potential of attenuated Mycobacterium tuberculosis or BCG vaccines to enhance oral SIV acquisition in infant macaquesWEAA0106LB Oral Abstract
A23CD4 T cell reconstitution following cART is immediate as is CD4+T cell depletion following treatment interruption: coupling the whole-body imaging of the CD4 pool and of the immune system activationWELBPE06 Poster Exhibition
A17Evolution of neutralizing antibodies in HIV-1 subtype C infectionWEPDA0101 Poster Discussion Abstract
A54HLA-B*58:02-specific benefit of MRKAd5 Gag/Pol/Nef vaccine in an African populationWEPDA0102 Poster Discussion Abstract
A2HIV-1 subtype C is significantly more infectious than other subtypesWEPDA0103 Poster Discussion Abstract
A2Functional differences in the viral accessory protein Nef between major HIV-1 subtypesWEPDA0104 Poster Discussion Abstract
A21 Viral clade affects the mechanism of HLA-B27:05-mediated immune control of HIVWEPDA0105 Poster Discussion Abstract
A5CXCR4 tropic HIV-1 is a cause of but not a result of CD4+ T cell count depressionWEPEA100 Poster Exhibition
A5Deciphering the interactions between the V1V2 domain of the HIV-1 envelope protein gp120 and α4ß7 integrin of the host cellWEPEA101 Poster Exhibition
A6Investigation of the sequential development of integrase strand transfer inhibitor resistance mutations in HIVWEPEA102 Poster Exhibition
A6Use of amplification refractory mutation system PCR assay as a simple and cost-effective tool to detect HIV-1 drug resistance mutationsWEPEA103 Poster Exhibition
A6Identification of HIV aberrant strains in CameroonWEPEA104 Poster Exhibition
A6Withdrawal of dolutegravir in early phases of HIV-1 infection in tissue culture does not abrogate antiretroviral activityWEPEA105 Poster Exhibition
A7Development of an in vitro assay to assess the function of naturally occurring HIV-1 Vpu sequences without codon optimizationWEPEA106 Poster Exhibition
A8HIV-1 Rev regulates the expression of Tat and viral replication via modulation of NAD(P)H: quinine oxidoreductase 1 (NQO1)WEPEA107 Poster Exhibition
A8Analysis of in vivo splice site usage by HIV-1 transcripts through deep sequencing: high diversity of spliced RNA expression patterns and identification of new splice sitesWEPEA108 Poster Exhibition
A11Decreased interferon signature in HIV-1 viremic controllersWEPEA109 Poster Exhibition
A11Differential effects of cell-surface CD4 and tetherin on ADCC mediated by non-neutralizing and broadly neutralizing anti-HIV antibodies: the role of Nef and VpuWEPEA110 Poster Exhibition
A11PKR as a restriction factor during HIV-1 infection counteracted by virus-induced cellular mechanismsWEPEA111 Poster Exhibition
A12Comparison of gene expression profile between human and macaque dendritic cells infected with virus carrying or not Vpx-loaded particles and assessment of their pathogenic impactWEPEA112 Poster Exhibition
A13A pseudo-glycodendrimer inhibits DC-SIGN-mediated HIV trans-infection and interferes with DC-SIGN signalWEPEA113 Poster Exhibition
A13Investigation of which NK cell populations expressing or not NKG2A, KIR2DL3 or KIR3DL1 are activated by autologous HIV-infected CD4 T cellsWEPEA114 Poster Exhibition
A13Enhanced capacity of NK-cells from carriers of the protective KIR3DS1 homozygous genotype to inhibit HIV replication in autologous infected CD4 T cellsWEPEA115 Poster Exhibition
A13DNA methylation analysis of natural killer cells during HIV-1 infectionWEPEA116 Poster Exhibition
A13NK cells expressing self-inhibitory KIR2DL receptors exhibit a reduced capacity to inhibit HIV-1 replication in vitroWEPEA117 Poster Exhibition
A14Functional impairments of macrophages derived from HIV-1+ patients are partially reversed after beginning of HAARTWEPEA118 Poster Exhibition
A22HIV-1-infected patients under suppressive cART present with various patterns of persistent immune activation: the ACTIVIH studyWEPEA119 Poster Exhibition
A22The different patterns of immune activation in virologic responders are linked to various causal factorsWEPEA120 Poster Exhibition
A22Elevated levels of circulating nucleosomes in HIV-infected women: cause or consequence of chronic immune activation?WEPEA121 Poster Exhibition
A23HIV-infected individuals with suboptimal CD4 restration despite suppressive antiretroviral therapy exhibit altered CD4+ T cell subsets and escalated both CD4+ and CD8+ T cell exhaustionWEPEA122 Poster Exhibition
A23HIV-1 group M subtypes display differential rates of CD4 T cell declineWEPEA123 Poster Exhibition
A24Flow virometry: envelope heterogeneity on individual HIV-1 virionsWEPEA124 Poster Exhibition
A25Serum-derived bovine immunoglobulin (SBI)-induced changes in stool microbiota correlate with levels of microbial translocation (MT) and reduced mucosal damageWEPEA125 Poster Exhibition
A25Influence of HIV infection and antiretroviral therapy on the immune status and microbial translocation in HIV-infected children in VietnamWEPEA126 Poster Exhibition
A25TLR2 stimulation acts synergistically with acetate stimulation to promote HIV-1 infection of CD4 + T cellsWEPEA127 Poster Exhibition
A27Ethnicity impacts inflammatory and coagulation profile in HIV patientsWEPEA128 Poster Exhibition
A31IL18 and ALOX5AP mRNA levels are increased in HIV-infected individuals despite the use of HAARTWEPEA130 Poster Exhibition
A32Low frequency of HIV rebound after antiretroviral treatment interruptionWEPEA131 Poster Exhibition
A32Dynamic imaging of intracellular glutathione redox potential of HIV-1 infected macrophages and its exploitation by Mycobacterium tuberculosis through its lipidsWEPEA132 Poster Exhibition
A32Histone deacetylase inhibitors alter the accumulation of spliced HIV mRNA: implications for virus productionWEPEA133 Poster Exhibition
A32Purging HIV-1 from latent reservoirs using human methyltransferase inhibitorsWEPEA134 Poster Exhibition
A33Immunological markers associated with HIV persistence during ART identified by iterated conditional random forests analysisWEPEA135 Poster Exhibition
A33Transcriptional profiling identifies RORC and PPARG as two major mechanisms regulating HIV permissiveness in primary Th17 cellsWEPEA136 Poster Exhibition
A33Modulation of HERV family expression after treatment with HDAC inhibitorsWEPEA137 Poster Exhibition
A34Distinct HIV genetic populations in effector memory T cells after prolonged therapyWEPEA138 Poster Exhibition
A34Progressive contraction of the latent HIV reservoir around a core of less-differentiated CD4+ memory T cellsWEPEA139 Poster Exhibition
A34Quantification and replication competency of HIV-1 following latency disruption in CD4+ T cellsWEPEA140 Poster Exhibition
A34T cell immunity in testicular tissue of ART-treated HIV-infected subjects: results from the Orchid studyWEPEA141 Poster Exhibition
A34Extracellular ATP induces the rapid release of HIV-1 from virus containing compartments of human macrophagesWEPEA142 Poster Exhibition
A34CTLA-4-expressing memory CD4+ T cells are critical contributors to SIV viral persistenceWEPEA143 Poster Exhibition
A35Defining the unique biomarkers of latently infected T cellsWEPEA144 Poster Exhibition
A35Cell-associated HIV-1 unspliced to multiply spliced RNA ratio at 12 weeks ART correlates with markers of immune activation and apoptosis and predicts the CD4+ T cell count at 96 weeks ARTWEPEA145 Poster Exhibition
A35Defective HIV-1 proviruses in the latent reservoir can be transcribed and translated following latency reversalWEPEA146 Poster Exhibition
A35HIV-1 transcription is stable during frequent longitudinal sampling in aviremic patients on ART: implications for HIV cure researchWEPEA147 Poster Exhibition